Part of The Mesothelioma Center. Contact Us
Mesothelioma-Line.com.
Journal Articles on Mesothelioma: Cancer Information for Patients and Families

Archive for the 'Erlotinib (Tarceva®)' Category

Erlotinib (Tarceva®) news feed.

June 11th, 2008. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

Conclusions: The combination of erlotinib and bevacizumab was tolerated reasonably well, but there was no evidence of radiographic response. This study demonstrates the feasibility of conducting trials in mesothelioma patients who have failed first-line therapy. More therapeutic studies with effective agents are needed for these patients.
Posted in Bevacizumab (Avastatin), Chemotherapy, Erlotinib (Tarceva®), Full Archive, Treatment, Type of Assessment: | No Comments »

June 15th, 2007. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

Conclusion: Single-agent erlotinib was not effective in MPM, despite high expression of EGFR. Activation of the ERK and phosphatidylinositol 3-kinase/Akt downstream pathways are possible resistance mechanisms to EGFR TKI. The activated phosphatidylinositol 3-kinase/Akt pathway is a potential therapeutic target for MPM.
Posted in Determining Efficacy, EGFR, Erlotinib (Tarceva®), Full Archive, Kinase Inhibitors, New & Novel, Pleural, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »

September 25th, 2006. Biology and management of malignant pleural mesothelioma

Studies with anti-angiogenesis agents are ongoing. An improvement of the knowledge of major molecular pathways involved in malignant mesothelioma is needed in order to define proper targets for the systemic treatment of this disease.
Posted in Angiogenesis, Determining Efficacy, Erlotinib (Tarceva®), Full Archive, New & Novel, Treatment, Type of Assessment: | No Comments »
Goldberg, Persky & White, P.C. Mesothelioma Lawyers